Loading...

SinoMab BioScience Limited

3681.HK•HKSE
Healthcare
Biotechnology
HK$1.91
HK$-0.22(-10.33%)

SinoMab BioScience Limited (3681.HK) Stock Overview

Explore SinoMab BioScience Limited’s financial performance, market position, analyst ratings, and future outlook.

Meyka AI Score

B

Score: 59.8/100

Key Financials

Market Cap2.3B
P/E Ratio-10.14
EPS (TTM)$-0.19
ROE-0.79%

AI Price Forecasts

1 Week$1.97
1 Month$2.37
3 Months$0.97
1 Year Target$1.10

3681.HK Stock Analysis & Investment Overview

Our comprehensive AI-powered analysis of SinoMab BioScience Limited (3681.HK) provides investors with deep insights into the stock's performance, growth potential, and market positioning. With a Meyka AI Score of B, this stock demonstrates moderate investment characteristics based on our advanced machine learning models.

The current technical analysis reveals key indicators including an RSI of 67.91, suggesting the stock is in a neutral condition. Our forecasting models predict significant price movements, with a 12-month target of $1.10.

Key financial metrics showcase the company's fundamental strength, including a P/E ratio of -10.14 and a market capitalization of 2.3B. These metrics, combined with our AI analysis, provide a comprehensive view for both institutional and retail investors.

Technical Indicators

67.91RSI (14)
0.31MACD
49.37ADX
Stats data is not available for 3681.HKStats details for 3681.HK are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.
Analyst Recommendations data is not available for 3681.HKAnalyst Recommendations details for 3681.HK are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.

Company Profile

SinoMab BioScience Limited, a biopharmaceutical company, engages in the research, development, manufacture, and commercialization of therapeutics for the treatment of immunological diseases primarily monoclonal antibody (mAb)-based biologics. Its flagship product is SM03, a first-in-target anti-CD22 mAb, which is in Phase III clinical trial for the treatment of rheumatoid arthritis (RA), as well as in various clinical stages for other immunological diseases, such as systemic lupus erythematosus (SLE), Sjogren's syndrome (SS), and non-Hodgkin's lymphoma (NHL). The company also focuses on developing SN1011, a Bruton's tyrosine kinase inhibitor, which is in Phase II clinical trial for the treatment of pemphigus, as well as in phase 1 clinical trial to treat multiple sclerosis, SLE, and NMOSD. Its products under the preclinical stage comprise SM17 for the treatment of asthma, atopic dermatitis, and idiopathic pulmonary fibrosis; SM06 to treat RA, SLE, NMOSD, and SS; SM09 for the treatment of NHL and RA; and TNF2 for the treatment of autoimmune diseases. The company operates in Mainland China, the Cayman Islands, and Hong Kong. SinoMab BioScience Limited was incorporated in 2001 and is headquartered in Pak Shek Kok, Hong Kong.

CEO

Shui On Leung

Employees

95

Headquarters

No.15 Science Park West Avenue, Tai Po

Founded

2019

Frequently Asked Questions

;